Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05498792 · ClinicalTrials.gov registry record · Early Phase 1
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
A Early Phase 1 study of Locally Advanced or Metastatic Melanoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05498792 is a Early Phase 1 study of Locally Advanced or Metastatic Melanoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05498792, a Early Phase 1 study of Locally Advanced or Metastatic Melanoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG CBL0137
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2026-09-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05498792
The ClinicalTrials.gov registry entry for NCT05498792 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT05498792 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05498792 about?
NCT05498792 is a clinical study titled "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma". Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma w...
What is the current status of trial NCT05498792?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2022-11-30. Estimated completion is 2026-09-02.
What conditions does trial NCT05498792 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Melanoma.
What interventions are being tested in trial NCT05498792?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), CBL0137 (DRUG).
Who is sponsoring clinical trial NCT05498792?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05498792 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.